Bright Minds Biosciences (XCNQ:DRUG) Days Inventory : 0.00 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Bright Minds Biosciences's Average Total Inventories for the three months ended in Dec. 2024 was C$0.00 Mil. Bright Minds Biosciences's Cost of Goods Sold for the three months ended in Dec. 2024 was C$0.00 Mil.

The historical rank and industry rank for Bright Minds Biosciences's Days Inventory or its related term are showing as below:

XCNQ:DRUG's Days Inventory is not ranked ^*
in the Biotechnology industry.
Industry Median: 177.045
* Ranked among companies with meaningful Days Inventory only.

Bright Minds Biosciences's Days Inventory stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Bright Minds Biosciences Days Inventory Historical Data

The historical data trend for Bright Minds Biosciences's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Days Inventory Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Sep24

Days Inventory

Bright Minds Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Bright Minds Biosciences's Days Inventory

For the Biotechnology subindustry, Bright Minds Biosciences's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bright Minds Biosciences's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Days Inventory distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's Days Inventory falls into.

Save Embed

;

Save Embed

;

Bright Minds Biosciences Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Bright Minds Biosciences's Days Inventory for the fiscal year that ended in Sep. 2024 is calculated as

	Days Inventory (A: Sep. 2024 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Sep. 2023 )	+	Total Inventories (A: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (A: Sep. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Bright Minds Biosciences's Days Inventory for the quarter that ended in Dec. 2024 is calculated as:

	Days Inventory (Q: Dec. 2024 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Sep. 2024 )	+	Total Inventories (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Bright Minds Biosciences (XCNQ:DRUG) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Bright Minds Biosciences's Inventory Turnover for the three months ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Bright Minds Biosciences's Inventory to Revenue for the three months ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Bright Minds Biosciences Days Inventory Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

DRUG:USA

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Executives

Jan Torleif Pedersen	Director
Nils Bottler	Director
Ryan Cheung	Senior Officer
Jeremy Fryzuk	Director
Alan Kozikowski	10% Security Holder, Director, Senior Officer
Ian Mcdonald	Director